Djabir Yulia Yusrini, Arsyad M Aryadi, Sartini Sartini, Lallo Subehan
Laboratory of Clinical Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia.
Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
Pharmacognosy Res. 2017 Apr-Jun;9(2):168-173. doi: 10.4103/pr.pr_129_16.
Doxorubicin (DOX) is a potent chemotherapy agent; however, its use may lead to cardiac, hepatic, and renal dysfunction. L extract contains antioxidant compounds that have been shown to reduce chemical-induced hepatotoxicity.
This study aimed to examine the protective effects of sp. extract to reduce DOX acute toxicities.
Thirty male rats were assigned to the following groups: Group I as controls, Group II was given DOX i.p. injection (25 mg/kg); Groups III, IV, and V were treated with sp. extract 100, 250, and 500 mg/kg orally for 5 days, respectively, prior to DOX i.p. injection. After 24 h, blood and organs were analyzed for biomarker levels and histopathological changes.
DOX treatment in Group II significantly increased creatine kinase-MB (CK-MB), aspartate transaminase (AST), alanine transaminase (ALT), and urea levels compared to controls. sp. extract at any given dose significantly improved ALT and AST; yet, CK-MB levels only reduced with 250 mg/kg dose (Group IV). Urea and creatinine levels in sp. groups were also lower compared to DOX-treated rats, but it was not significant. Histopathological analysis showed improved liver, heart, and renal tissue structures in sp-treated rats, especially at higher doses.
sp. extract at any dose given protected the rats from liver toxicity, but only at dose 250 mg/kg reduced cardiac toxicity. Although renal biomarkers were insignificantly lower, renal architecture was improved with sp. treatment.
Doxorubicin (25 mg/kg) i.p injection led to elevated ALT, AST, CK-MB and urea levels in rats.At the given dose, doxorubicin induced pathological changes in cardiac, liver and renal tissues.Pretreatment with sp. extract prior to doxorubicin injection significantly reduced the elevation of ALT, AST and CK-MB, especially at the dose of 250 mg/kg.Improvement in histological structures of cardiac, liver and renal tissues was shown in sp. (250 mg/kg) treated rats, indicating a protective effect of the extract on doxorubicin acute toxicity. DOX: Doxorubicin; CK-MB: creatine kinase-MB, AST: Aspartate transaminase; ALT: Alanine transaminase.
阿霉素（DOX）是一种强效化疗药物；然而，其使用可能导致心脏、肝脏和肾脏功能障碍。L提取物含有抗氧化化合物，已被证明可降低化学诱导的肝毒性。
本研究旨在检测sp.提取物对减轻DOX急性毒性的保护作用。
将30只雄性大鼠分为以下几组：第一组为对照组，第二组腹腔注射DOX（25mg/kg）；第三组、第四组和第五组在腹腔注射DOX前，分别口服sp.提取物100、250和500mg/kg，持续5天。24小时后，分析血液和器官中的生物标志物水平及组织病理学变化。
与对照组相比，第二组DOX治疗显著提高了肌酸激酶-MB（CK-MB）、天冬氨酸转氨酶（AST）、丙氨酸转氨酶（ALT）和尿素水平。任何给定剂量的sp.提取物均显著改善了ALT和AST；然而，CK-MB水平仅在250mg/kg剂量时降低（第四组）。sp.组的尿素和肌酐水平也低于DOX治疗的大鼠，但差异不显著。组织病理学分析显示，sp.治疗的大鼠肝脏、心脏和肾脏组织结构得到改善，尤其是在较高剂量时。
任何给定剂量的sp.提取物均可保护大鼠免受肝脏毒性，但仅在250mg/kg剂量时可降低心脏毒性。虽然肾脏生物标志物略低，但sp.治疗改善了肾脏结构。
腹腔注射阿霉素（25mg/kg）导致大鼠ALT、AST、CK-MB和尿素水平升高。在给定剂量下，阿霉素诱导心脏、肝脏和肾脏组织发生病理变化。在阿霉素注射前用sp.提取物预处理可显著降低ALT、AST和CK-MB的升高，尤其是在250mg/kg剂量时。sp.（250mg/kg）治疗的大鼠心脏、肝脏和肾脏组织的组织结构得到改善，表明该提取物对阿霉素急性毒性具有保护作用。DOX：阿霉素；CK-MB：肌酸激酶-MB，AST：天冬氨酸转氨酶；ALT：丙氨酸转氨酶。
Zotero 插件